ZMapp is viewed by experts as the most promising experimental drug to fight Ebola. The Department of Health and Human Services provided nearly $25 million in funding to ZMapp’s manufacturer, and charities like the Bill and Melinda Gates foundation are trying to increase the drug's production.
ZMapp, which has shown successful testing in monkeys, is a cocktail of three genetically engineered antibodies that boosts a patients' ability to fight off Ebola by latching onto the virus and neutralizing it. ZMapp is a combination of two different serums made by two companies – Leaf Biopharmaceutical, an arm of Mapp Biopharmaceutical, Inc.; and Defyrus Inc